According to Future Market Insights research, during the projected period, the global Catheter Associated Urinary Tract Infections Treatment Market is expected to grow at a CAGR of 3.0%.
The market value is projected to increase from USD 1.31 Billion in 2023 to USD 1.76 Billion by 2033. The catheter associated urinary tract infections treatment market was valued at USD 1.26 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 3.9% in 2023.
| Attributes | Details |
|---|---|
| Market Size (2023) | USD 1.31 Billion |
| Projected Market Value (2033) | USD 1.76 Billion |
| Global Market Growth Rate (2023 to 2033) | 3.0% CAGR |
| Market Share of Top 5 Countries | 52.1% |
As assessed by Future Market Insights, among the drug type, quinolones held a market share of around 37.6% in the global market, in 2022. In 2022, the catheter associated urinary tract infections treatment market sales accounted for a revenue share of 72.3% in the global complicated UTI market, which was valued at around USD 1.8 Billion.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global market recorded a historic CAGR of 4.1% in the last 5 years from 2017 to 2022.
Catheter associated urinary tract infections (CAUTIs) are common complications associated with use of the catheters. Elderly individuals are more susceptible to UTIs due to weakened immune systems, and urinary retentions.
Moreover, individuals with compromised immune systems such as those with diabetics, or undergoing immunosuppressive therapy are at increased risk of UTIs.
These infections may also reoccur more frequently due to the body’s reduced ability to fight off the infection.
The growth of catheter associated urinary tract infections treatment market is due to the growing number of UTIs and recurrent UTIs. This has led to a higher demand for effective treatment choices.
The increasing prevalence of CAUTIs worldwide can be attributed to a variety of factors, including prolonged catheter use, inadequate catheter care and hygiene and other factors.
Patients may require catheterization for a prolonged time due to various medical conditions. Prolonged catheter use increases the opportunity for bacteria to colonise the urinary tract and cause infection. Proper maintenance and care of the urinary catheters are essential for the reduction of the infection.
Hence, the global catheter associated urinary tract infections treatment market is been driven by the high prevalence and incidence rate of the disease worldwide.
The demand for new treatment arises from the need to address antibiotic-resistant CAUTIs. As bacteria become resistant to traditional antibiotics, it becomes harder to treat these infections efficiently.
This increases the risk of the implication and prolonged hospital stays for patients and adds a financial burden on the healthcare system due to the increased cost of treating drug-resistant infections.
The prevalence of antibiotic-resistant CAUTIs is a significant concern as it limits the effectiveness of traditional antibiotic therapy. Moreover, the development of new antibiotics is slow and costly, and the pipeline for novel antibiotics is relatively dry. Moreover, this can be a significant factor affecting the growth of the CAUTIs market.
The USA accounted for around 18.2% market share in the global market in 2022. The USA market’s growth is expected to rise at an overall CAGR of 2.2% over the forecast period.
Urinary tract infection is one of the most frequent infectious diseases caused by bacteria. A complicated urinary tract infection can affect anyone, regardless of gender or age, and they are caused by anatomical or functional abnormalities in the urinary system.
An increase in chronic illness such as diabetes, and kidney disease, such as renal failure and bladder cancer, is driving the usage of catheters and other drainage devices among patients and the increased use of indwelling use of urinary catheters is the attributing factor in the rise of complicated UTIs. Complicated UTIs are generally more challenging to treat compared to uncomplicated UTIs, as they are associated with more severe symptoms and have a higher risk of complication.
These are the major factors that help the market grow exponentially in the USA, region.
The India market held around 10.2 % market share of the global market in 2022.
The large patient population in India is one of the reasons why the Indian market has a significant presence in the global catheter associated urinary tract infections treatment market.
With such a large population, the incidence and prevalence of CAUTIs are also higher.
Since CAUTI is a common healthcare-associated infection, the large patient population in India creates a high demand for CAUTIs treatment.
China held a market share of about 9.5% of the global market in 2022.
The Chinese government to improve healthcare outcomes and reduce healthcare-associated infections, including CAUTIs, has implemented several measures and programs.
The promotion of awareness and education regarding infection prevention measures is one significant initiative. The aim is to increase awareness among healthcare providers and patients about the risk associated with CAUTIs and the importance of preventing the infection.
The government provides training and education to healthcare providers to enhance their knowledge and skills in preventing CAUTIs. Additionally, they focus on this effort. In addition, supporting the adoption of infection prevention measures in healthcare facilities. China is in demand for the market of catheter-associated urinary tract infections.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The Quinolones sub-segment held around 37.6% share of the global market in 2022 within the drug type.
Quinolones have a broad-spectrum antimicrobial activity. In addition, Gram-negative organism commonly causes CAUTIs, and quinolones have demonstrated efficacy against these pathogens. In addition, quinolones have the ability to achieve high concentration in the urine, which is desirable for treating urinary tract infections.
Quinolones also have good penetration in the tissue of the urinary tract, including the bladder wall, renal parenchyma and prostate gland.
They are also available in both oral and intravenous formulations providing convenience and flexibility in the treatment of CAUTIs.
The Asymptomatic CAUTI (Bacteriuria) segment held around 58.9% share of the total market in 2022 within the indication type.
In comparison to symptomatic CAUTIs, asymptomatic CAUTIs are more common. Many patients with urinary catheters may not exhibit common infection symptoms, such as fever or pain, making it difficult to detect these infections without specialized testing.
The greater prevalence of asymptomatic CAUTIs contributes to its dominant position in the indication type segment.
Retail pharmacies hold a share of about 43.2% in 2022, within the global market.
Medication used in the treatment of CAUTIs is mainly distributed through retail pharmacies, which serve as the main distribution hubs. To ensure that patients have access to necessary antibiotics and other relevant drugs, they make sure that these medications are available.
In retail settings, pharmacists and pharmacy staff offer education and counselling to patients about the correct use of medication for CAUTIs. These are the services provided by them. Retail pharmacies offer a variety of over-the-counter products that can assist in managing CAUTIs in addition to the prescribed medication.
The treatment market for catheter-associated urinary tract infections treatment is competitive. In addition to expanding their presence in emerging markets through new partnerships and merger acquisitions, market leaders are concentrating on the introduction of technologically advanced products.
The competitive environment includes an analysis of a handful of global and local corporations that control the majority of the market share. In addition to acquisitions, mergers, and partnerships with key market participants.
Some key instances of development include:
Similarly, the team at Future Market Insights has tracked recent developments related to companies in the catheter associated urinary tract infections treatment market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa. |
| Key Countries Covered | USA, Canada, Brazil, Argentina, Mexico, Germany, France, UK, Italy, Spain, Russia, BENELUX, India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, Türkiye, GCC Countries, Northern Africa, and South Africa |
| Key Market Segments Covered | Drug Type, Indication, Distribution Channel and Region |
| Key Companies Covered | Pfizer Inc.; Merck & Co., Inc.; GlaxoSmithKline (GSK); AstraZeneca; Bayer AG; Johnson & Johnson; Novartis International AG; Sanofi; Roche Holding AG; Eli Lilly and Company; Bristol-Myers Squibb Company; Abbott Laboratories; Astellas Pharma Inc.; Boehringer Ingelheim; Daiichi Sankyo Company, Limited; Gilead Sciences, Inc.; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Lupin Limited |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market is expected to be valued at USD 1.31 billion in 2023.
AstraZeneca, Bayer AG, and Sanofi are the key market players.
Increased prevalence of chronic illnesses like diabetes drives catheter usage.
Retail pharmacies hold a share of about 43.2% in 2022.
The market is estimated to reach USD 1.76 billion by 2033.
| Market Estimated Size in 2024 | USD 770.0 million |
|---|---|
| Projected Market Value in 2034 | USD 1,432.0 million |
| Value-based CAGR (2024 to 2034) | 6.4% |
| Estimated Market Size in 2024 | USD 11,244.0 million |
|---|---|
| Projected Market Value in 2034 | USD 13,617.4 million |
| Value-based CAGR (2024 to 2034) | 1.9% |
| Expected Market Value (2023) | USD 6.55 Billion |
|---|---|
| Anticipated Forecast Value (2033) | USD 17 Billion |
| Projected CAGR (2023 to 2033) | 10% |
| Expected Market Value (2023) | USD 3.44 billion |
|---|---|
| Anticipated Forecast Value (2033) | USD 7.5 billion |
| Projected Growth Rate (2023 to 2033) | CAGR 8.11% |
Explore Therapy Area Insights
View Reports
Catheter Associated Urinary Tract Infections (UTI) Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
